RENX.L

Renalytix plc
Renalytix PLC - Result of AGM
19th December 2024, 11:16
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 7887Q
Renalytix PLC
19 December 2024
 

Renalytix plc

("Renalytix" or the "Company")

 

Result of AGM

 

LONDON and NEW YORK, 19 December 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), which is commercialising the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment for chronic kidney disease, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

 

The results of the AGM are detailed below:

 

 For

 % voted in favour

 Against

 % voted against

 Withheld

Ordinary resolutions

 





1 Receive and adopt the UK 2024 Annual Report

215,649,238

99.86%

298,365

0.14%

40,760

2 Approve Directors' Remuneration Report

187,117,898

86.76%

28,544,007

13.24%

326,458

3 Ratify the selection of CohnReznick

215,624,372

99.92%

178,413

0.08%

185,578

4 Reappoint PKF Littlejohn LLP as Auditors

215,760,810

99.91%

184,281

0.09%

43,272

5 Authorise Board to determine auditors' remuneration

215,474,022

99.86%

302,821

0.14%

211,520

6 Authorise the issue of shares under the 2020 Equity Incentive Plan with Non-Employee Sub-Plan

151,371,930

83.99%

28,863,246

16.01%

35,753,187

7 Authorise the Issue of Equity

151,554,272

83.99%

28,898,602

16.01%

35,535,489







Special resolutions

 





8 Authorise Issue of Equity without Pre-emptive Rights

151,648,214

84.04%

28,799,536

15.96%

35,540,613

9 Authorise Market Purchase of Ordinary Shares

180,179,511

99.83%

305,940

0.17%

35,502,912

 

 

For further information, please contact:

 

Renalytix plc

www.renalytix.com

James McCullough, CEO

Via Walbrook PR



Stifel (Nominated Adviser and Joint Broker)

Tel: 020 7710 7600

Nicholas Moore / Nick Harland / Ben Good




Oberon Capital (Joint Broker)

Tel: 020 3179 5300

Mike Seabrook / Nick Lovering




Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Alice Woodings

Mob: 07980 541 893 / 07407 804 654



CapComm Partners


Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

 

 

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.

 

The over 10,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO). 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBBBDDDBBDGSC]]>
TwitterFacebookLinkedIn